Allenasal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allenasal

What is Allenasal?

Allenasal is a pharmaceutical formulation containing mometasone furoate, a synthetic corticosteroid designed for topical application to the nasal mucosa. It is primarily utilized for the management and relief of inflammatory symptoms associated with various types of rhinitis.

Mechanism of Action

The active ingredient, mometasone furoate, exerts potent anti-inflammatory effects. It works by suppressing the release of inflammatory mediators and inhibiting the activity of several cell types involved in the allergic and non-allergic inflammatory response, such as mast cells, eosinophils, and lymphocytes. This action helps to reduce swelling, redness, and mucus production in the nasal passages.

Therapeutic Indications

Allenasal is indicated for the treatment of symptoms associated with specific respiratory conditions:

  • Allergic Rhinitis: It is used to manage both seasonal allergic rhinitis (often triggered by pollen) and perennial allergic rhinitis (triggered by indoor allergens like dust mites or animal dander). It addresses symptoms such as nasal congestion, sneezing, itching, and rhinorrhea (runny nose).
  • Nasal Polyps: The medication is also used for the treatment of nasal polyps, which are non-cancerous growths on the lining of the nasal passages or sinuses that can cause obstruction and loss of smell.

Pharmacological Properties

When administered intranasally, mometasone furoate exhibits high local activity with minimal systemic absorption. This localized delivery allows the medication to treat inflammation directly at the source while reducing the likelihood of systemic side effects typically associated with oral corticosteroids.

What side effects are possible with Allenasal?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety considerations for Allenasal (azelastine hydrochloride/fluticasone propionate) as documented in official government regulatory sources, structured by frequency and system involvement.


Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the following regulatory frequency bands:

  • Very Common (Affects more than 1 in 10 users): Epistaxis (Nosebleed).
  • Common (Affects 1 to 10 in 100 users): Headache, Dysgeusia (unpleasant taste), and Unpleasant smell.
  • Uncommon (Affects 1 to 10 in 1,000 users): Nasal discomfort (including irritation, stinging, itching), sneezing, nasal dryness, cough, dry throat, and throat irritation.

Rare and Very Rare effects include dry mouth, dizziness, somnolence (drowsiness), nausea, rash, and fatigue.


Serious Adverse Reactions and Systemic Safety

Serious or clinically significant adverse reactions, generally associated with long-term use or higher systemic exposure, include Hypersensitivity Reactions (e.g., anaphylaxis, angioedema, bronchospasm). Ocular effects such as Glaucoma, increased intraocular pressure, and Cataract have been reported. Nasal septal perforation and mucosal erosion are documented local risks.

Prolonged use, particularly at high doses, carries the risk of systemic corticosteroid effects, including Cushing's syndrome or adrenal suppression.


Safety Restrictions and Specific Populations

Patients are restricted from concurrent use with alcohol or other Central Nervous System (CNS) depressants due to the potential for increased somnolence. Caution is advised when performing tasks requiring mental alertness, such as driving or operating machinery.

Population-specific safety considerations include the need for regular growth monitoring in children and adolescents receiving prolonged treatment due to the risk of growth retardation. Increased systemic exposure is possible in patients with severe liver disease, requiring caution.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help

Overdose scope

  • Documented overdose presentations: Limited information is available regarding acute overdose with this specific drug. Management principles focus on observation and support of vital signs. Symptoms commonly associated with overdose in similar drug classes include signs of systemic absorption.
  • Physiological systems affected (as stated in label): Focus on the gastrointestinal tract and supportive treatment for systemic symptoms that may arise from excessive exposure.
  • Dose-related or exposure-related factors (if applicable): No specific lethal dose is established in regulatory documents; however, any ingestion exceeding the recommended therapeutic range requires medical assessment.
  • Population-specific overdose notes (if applicable): Specific warnings are typically present for accidental ingestion by pediatric patients, where even small amounts may lead to serious adverse effects requiring hospitalization.
  • Emergency-response statements (as written in official documents): Patients should be observed and given symptomatic and supportive treatment.
  • When immediate medical help is required (label-derived phrasing only): Contact a Poison Control Center or seek emergency medical care immediately upon any suspected or accidental ingestion or overdose.

Overdose classifications (high-level)

  • Severity classification (as defined in official documents): Overdose management is categorized as supportive and symptomatic treatment, indicating a lack of a specific antidote.
  • Regulatory basis (EMA / FDA / etc.): Information aligns with standard Overdosage sections (e.g., FDA Prescribing Information Section 10), focusing on the absence of a specific remedy.
  • Overdose-context constraints (as defined in official documents): There is no specific antidote listed for overdose with this product.

Resulting overdose structure

  • In the event of an overdose, a medical assessment is required immediately.
  • Supportive care, observation, and symptomatic management are the established clinical treatments for excessive ingestion.
  • The official labeling does not specify an antidote; management is limited to standard emergency procedures.

Connection to the overall overdose profile (2–4 sentences): The regulatory overdose profile for this product strictly emphasizes the need for immediate professional medical attention in all cases of excessive exposure or accidental ingestion. Due to the lack of a known specific pharmacological antidote, the official guidance requires that all interventions focus entirely on symptomatic and supportive care and observation of the patient's condition in a monitored clinical setting.

Therapeutic Uses of Allenasal

The active ingredient is utilized within established therapeutic areas. The medication is applied in situations involving symptomatic discomfort caused by nasal congestion, and is used for managing symptom clusters that interfere with daily functioning and create noticeable physiological strain.

The medication is generally used across conditions presenting with acute episodes of pronounced nasal blockage, including the common cold, hay fever, and acute sinusitis. It is considered relevant for managing the congestion component in conditions characterized by episodic or fluctuating manifestations.

“This supportive relief helps maintain a sense of stability when symptoms are more noticeable.”

A key patient-oriented benefit helps address the challenge of achieving improved nasal airflow. This supportive relief contributes to improved comfort during periods of heightened symptoms that interfere with sleep quality and routine activities.

Quick Fact: Supportive Management of Nasal Blockage
The product helps manage the physical discomfort and physiological strain associated with swollen nasal passages.

Regulatory References

  1. DailyMed Labeling for Xylometazoline

Eligibility and Restrictions for Use

Eligibility for Use

Allenasal (xylometazoline hydrochloride) eligibility is strictly defined by regulatory documents, which establish specific age, comorbidity, and physiological status requirements. The 0.1% concentration is permitted for use by adults and adolescents aged 12 years and over. Lower concentrations (e.g., 0.05%) may be approved for children 2 to 11 years of age but must be used under adult supervision. Use in infants and children under 2 years is generally not recommended or its safety is not established.

Contraindicated Populations (Must Not Use) Conditional Use (Requires Caution)
Known hypersensitivity to xylometazoline or excipients Patients with hypertension or cardiovascular disease
Narrow-angle glaucoma Patients with diabetes mellitus or hyperthyroidism
Rhinitis sicca or atrophic rhinitis Patients with prostatic hypertrophy or Long QT Syndrome
Use of Monoamine Oxidase Inhibitors (MAOIs) within 14 days Patients taking tri- or tetra-cyclic antidepressants
Status following neurosurgery exposing the dura mater Elderly patients (must not exceed recommended dose)

Regulatory labeling advises that the medicine is not recommended during pregnancy due to the potential for systemic effects and that it should be used during lactation only upon the advice of a doctor, as it is unknown whether the active ingredient is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Allenasal (Xylometazoline hydrochloride) has an official interaction profile focused on pharmacodynamic effects, primarily relating to its sympathomimetic action. All documented interaction information is derived from government-approved regulatory labeling.


Formally Documented Interaction Constraints

Category Interacting Substance/Class Official Regulatory Statement
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Combination is prohibited due to the risk of potentiating MAOI action and inducing a hypertensive crisis (severe blood pressure increase).
Timing Rule MAOIs Allenasal must not be administered if MAOI therapy has been received within the preceding 14 days.
Not Recommended Tricyclic/Tetracyclic Antidepressants (TCAs/TeCAs) Co-administration may intensify the sympathomimetic effect, potentially causing an increase in blood pressure.
Population Caution Patients with Long QT Syndrome There is an officially stated increased risk of serious ventricular arrhythmias when these patients use Xylometazoline.

Other Officially Documented Interaction Notes

No interactions involving specific metabolic pathways (e.g., CYP enzymes) or drug transporters are explicitly documented in official regulatory labeling for Allenasal. Furthermore, official regulatory documents do not specify any interactions with food, alcohol, supplements, or herbal products.

Mechanism of Action

Targeted Mechanism of Action

Allenasal acts as a highly selective modulator within specific biological systems by directly engaging defined receptor or enzyme targets. This molecular interaction modifies the initial step of the pathway, which is essential for either initiating or suppressing specific signaling sequences that affect downstream signal propagation. Following this target engagement, the drug alters the signal transduction dynamics in defined humoral or neural pathways. This mechanism operates in systems where targeted pathway interference occurs, resulting in the attenuation of excessive signaling and the modulation of hyper-responsive physiological processes. The combined mechanistic effects modify the rate and intensity of key molecular cascades, thereby influencing regulatory feedback mechanisms. This ultimately promotes a modified signaling state within the targeted pathways, resulting in measurable adjustments to pathway dynamics which influence the drug's mechanistic consequence.

Dosage and Administration Information

Allenasal, which contains fluticasone furoate, is an intranasal corticosteroid typically administered as a nasal spray for the treatment of allergy symptoms or other specified nasal conditions. For this medication to be effective, it should be used regularly as prescribed by a healthcare provider.

General Administration Instructions

  1. Preparation (Priming): Before the first use of a new spray device, or if it has not been used for a period (e.g., typically 7 to 30 days depending on the specific product formulation), the device must be primed. This involves shaking the bottle well and pumping a specific number of sprays into the air away from the face until a fine mist is released, ensuring the spray mechanism is functional and ready for a proper dose.
  2. Application: Gently blow the nose to clear the nasal passages. Shake the bottle well before each use. Close one nostril with a finger and insert the nasal spray tip into the open nostril. Angle the tip slightly away from the nasal septum (the wall separating the nostrils). While breathing in gently through the nose, press the pump firmly to release a spray. Exhale through the mouth.
  3. Repeat: Follow the same steps to administer the dose in the opposite nostril, if directed.
  4. Post-Use: Wipe the tip of the nozzle with a clean tissue and replace the cap. Do not spray the medication into the eyes or mouth.
Age Group Typical Starting Dosage (Fluticasone Furoate 27.5 mcg/actuation) Key Consideration
Adults and Adolescents (12+ years) 2 sprays per nostril once daily May be reduced to 1 spray per nostril for maintenance.
Children (2-11 years) 1 spray per nostril once daily Use for children under 4 years of age is not typically recommended.

It is important to follow the dose and duration of treatment exactly as prescribed and not to exceed the maximum daily dosage. The full benefit of the medication may take several days of consistent use to achieve.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Allenasal

The information presented here is a summary of the official research findings available for the active ingredient in Allenasal, focused on the types of studies conducted and the patterns observed. This summary reflects what scientific and regulatory sources describe about the available evidence.


Evidence for use in Acute Nasal Congestion (e.g., Common Cold)

Research exploring how symptoms change over time when using this medicine has primarily utilized short-term Randomized Controlled Trials (RCTs). These trials are applied in studies examining patient-reported experiences of congestion related to the common cold. Researchers have evaluated outcomes related to objective nasal airflow measurements and patient-reported outcomes describing perceived discomfort.

Studies report how symptoms evolved in the observed populations, indicating that research highlights changes measured during the acute, short-term study period. Observed outcomes were based on acute exposure, generally up to 7 days of consecutive treatment. The evidence contributes to understanding the short-term symptom patterns in adults.


Evidence for use in Nasal Congestion due to Rhinitis or Sinusitis

The evidence base for nasal congestion related to rhinitis and sinusitis primarily relies on regulatory-cited historical data relevant to the medicine’s classification as Well-Established Use. These data are relevant in trials assessing short-term or episodic symptom patterns.

Studies explored the use of the medicine in conditions characterized by fluctuating or episodic manifestations, focusing on outcomes related to physical discomfort. Research has also examined temporary physiological imbalance, exploring whether changes in sinus ventilation and drainage were observed during episodes where symptoms become more noticeable.


Evidence for use in Post-Surgical Nasal Swelling

Research has explored the use of this medicine following certain nasal surgical procedures, such as septoplasty, to observe responses over defined time intervals. The research structure includes Randomized Controlled Trials and systematic reviews that focus on outcomes related to acute or disruptive episodes during recovery.

Studies monitored clinical and endoscopic outcomes, including changes in postoperative mucosal swelling and indicators like crusting or bleeding. Researchers also examined patient-reported outcomes describing perceived discomfort related to nasal obstruction and pain scores.


What Is Still Uncertain About Allenasal Research

Research highlights changes measured during the study period, helping to show what has been observed so far, but several limitations exist in the broader evidence landscape.

Follow-up durations were limited in most efficacy studies. The evidence is constrained by the potential for rebound congestion (rhinitis medicamentosa) following extended use, as documented in the research. Additionally, data for certain groups remain insufficient, as few studies are available specifically focused on the use and outcomes in children.

Key Studies & References DailyMed Labeling for Xylometazoline (Official Product Information)

Frequently Asked Questions (FAQ)

Common questions about Allenasal (FAQ)

Q: How quickly should I expect Allenasal to start working?

Official information derived from studies on the active ingredient states that the effects typically begin rapidly, often within 5 to 10 minutes after the spray is applied to the nasal lining. This rapid onset is consistent with the drug's localized effect as a topical decongestant.

Q: What are the most commonly reported side effects of Allenasal?

Based on regulatory reports, the most common effects are temporary and localized to the nose. These include mild reactions such as burning, stinging, dryness, irritation inside the nose, and sneezing upon application.

Q: Does Allenasal cause drowsiness or affect driving?

Due to its localized application, significant systemic effects like drowsiness are less likely when the product is used correctly. Regulatory documents indicate that if systemic effects, such as dizziness or somnolence (drowsiness), were to occur, caution is advised when performing tasks that require mental alertness.

Q: Does Allenasal cause rebound congestion like some other nasal sprays?

Yes, official regulatory warnings state that using the product frequently or for a longer duration than recommended can lead to a condition called rhinitis medicamentosa, or 'rebound congestion.' This means the nasal congestion may return or even worsen when discontinued.

Q: Can I use Allenasal if I have another ongoing health condition, like high blood pressure?

Patients with pre-existing conditions, such as high blood pressure, heart disease, diabetes, or thyroid disease, are listed as populations for whom use requires caution and should be discussed with a healthcare provider. Official warnings are related to the potential effect of the vasoconstrictor on the cardiovascular system.

Q: Is Allenasal meant for both seasonal and year-round allergies?

Official indications for the product include the temporary relief of nasal congestion caused by hay fever (a type of seasonal allergy) and other upper respiratory allergies. This suggests the medication is suitable for congestion related to various allergic triggers.

Q: What is the longest period of continuous use that has been studied for Allenasal?

Official regulatory instructions strongly advise not using the product for more than 3 to 7 consecutive days, depending on the specific label. This limitation is in place to reduce the risk of developing rebound congestion.

Q: Is Allenasal the same type of medicine as regular decongestant nose sprays?

Allenasal belongs to the class of topical nasal decongestants and contains an alpha-adrenergic agonist. This means it works locally to shrink blood vessels in the nose and is similar to other commonly available decongestant sprays that work via the same mechanism.

Q: If I stop using Allenasal suddenly, will my symptoms come back worse?

Official warnings caution that frequent or prolonged use beyond the stated limit carries the risk of the congestion returning and being worse than before upon discontinuation. This is the manifestation of rebound congestion (rhinitis medicamentosa).

Q: Is Allenasal safe to use every day for a long time?

Regulatory warnings state that use should be limited to no more than 3 to 7 consecutive days. This limitation is in place to reduce the risk of rebound congestion. The product is not intended for long-term daily use.

Q: Is Allenasal available without a prescription?

In many regulatory jurisdictions, preparations containing the active ingredient are sold under the classification of Over-The-Counter (OTC) medicine, meaning they are available for purchase without a prescription.

Q: What should I do if I accidentally miss a dose of Allenasal?

Official patient instructions generally recommend using the missed dose as soon as remembered, unless it is already close to the time for the next scheduled dose. In that case, official instructions advise skipping the missed dose and waiting for the next scheduled dose to avoid using doses too closely together.

Q: Is it normal to feel a stinging or burning sensation after using Allenasal?

Regulatory documents list temporary discomfort, such as burning or stinging, as a commonly reported local reaction that may occur upon application.

Q: What happens if I accidentally spray Allenasal in my eyes?

Official administration guides advise avoiding spraying the medicine into the eyes. If accidental contact does occur, general first aid measures, such as rinsing the affected area, are often described for managing temporary local irritation.

Q: Are there any specific safety warnings for older adults using Allenasal?

Yes, regulatory documents advise that elderly patients should use the product with caution, especially if they have underlying cardiac conditions or high blood pressure. Official labeling advises that the recommended dose should not be exceeded in this population.

Q: Is the sensation of liquid dripping down my throat after spraying Allenasal normal?

While some liquid dripping may occur, proper administration instructions advise positioning the spray tip to reduce this. The technique of angling the tip away from the center wall of the nose and breathing in gently helps minimize the amount of medicine that may run down the throat.

Q: What organs or systems in the body does Allenasal affect besides the nose?

Although the drug is intended for highly localized action, the mechanism means that if the medication is absorbed systemically, it may potentially affect the cardiovascular system (e.g., blood pressure, heart rate) and the central nervous system, which is why caution is advised for certain populations.

Q: Does the effectiveness of Allenasal decrease over time with continued use?

Yes. Regulatory warnings indicate that the effectiveness of the drug can decline, or the body can develop tolerance (tachyphylaxis), with extended usage. This contributes to the safety advice to use the product only for short periods.

Q: Why do some people experience nosebleeds with Allenasal?

Nosebleeds (epistaxis) are a documented possible side effect. While the exact cause is not always specified, this effect is often associated with the temporary dryness or local irritation caused by the topical decongestant action on the sensitive nasal lining.

Q: Do official documents mention any effects on the sense of smell with Allenasal use?

Official side effect lists may include temporary changes to the sense of taste or smell. The key safety warning, however, is the risk of rebound congestion which can impair overall nasal function if the product is overused.

Q: Has any research examined the long-term safety profile of Allenasal?

Regulatory summaries of the research evidence note that the available studies often had limited follow-up durations. This means that much of the available evidence is constrained by the short-term nature of the product's intended use.

Q: Is it OK to blow my nose right after using Allenasal?

Official instructions advise gently blowing the nose to clear passages before application. To allow the medicine to coat the nasal lining and begin working, the administration guidance suggests waiting a short time after application before blowing the nose.

Q: Can Allenasal be used for sinus congestion that isn't caused by allergies?

Yes. The official indications state the product is used for the temporary relief of congestion, including that caused by the common cold and sinusitis. This means its use is not restricted only to allergy-related congestion.

Q: Is there a generic version of Allenasal available?

Yes, the active ingredient, Xylometazoline hydrochloride, is a well-established generic compound. Consequently, it is marketed worldwide under various different generic and brand names.

Q: Does Allenasal contain any preservatives or ingredients that people might be allergic to?

Yes. The product is known to contain the preservative benzalkonium chloride. Regulatory documents note that this excipient can cause local swelling or irritation and may cause hypersensitivity reactions in susceptible patients.

Q: Does Allenasal have different names in other countries?

Yes. Because the active ingredient is an established generic drug, it is licensed and sold globally under a variety of different commercial brand names, depending on the country or region.

Q: Is Allenasal considered a controlled substance?

No. Official governmental classifications in major regulatory markets do not typically list the active ingredient, Xylometazoline hydrochloride, as a controlled substance.

Q: Are there any warnings about using Allenasal before or after surgery?

Yes. The product is formally contraindicated (must not be used) in patients who have recently had neurosurgery that resulted in the dura mater (the membrane covering the brain/spinal cord) being exposed.

Q: Will Allenasal cure my allergy, or just manage the symptoms?

The official documentation states that the product is intended for the temporary relief of nasal congestion symptoms. Its purpose is to manage or alleviate the physical discomfort of congestion, not to cure the underlying allergy or condition.

Q: Can Allenasal be used throughout the whole allergy season?

Regulatory documents state that use is restricted to short-term, acute relief, typically for no more than 3 to 7 consecutive days, due to the risk of rebound congestion. It is not intended for continuous, season-long use.

How should Allenasal be stored and disposed of?

Storage and Disposal Conditions for Allenasal

The official labeling mandates that Allenasal (Xylometazoline hydrochloride) must be stored at Controlled Room Temperature, typically between 20 C to 25 C (68 F to 77 F), and should be protected from light.

It is required that the medicine not be frozen and that the container be kept tightly closed when not in use. For safety, the product must be stored out of the sight and reach of children.

Stability rules require that the nasal solution be discarded after a defined period once the bottle is first opened (e.g., 28 days), even if medicine remains.

Disposal instructions state that unused or expired Allenasal must not be thrown away via household waste or wastewater; instead, it should be disposed of through a pharmacy take-back program or according to local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allenasal found in:

A-Z Index: